# MCLA-129

Source: https://onco.cc/drugs/mcla-129/  
OnCo record `mcla-129` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.

## Summary

MCLA-129 is a bispecific antibody developed by Betta Pharmaceuticals and Merus. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival. ClinicalTrials.gov describes the intervention as: MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumour growth and survival. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer. The largest, NCT04930432, plans to enrol 400 participants with primary completion expected 2028-04-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: bispecific
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival.

## Sources

- ClinicalTrials.gov: trials of MCLA-129: https://clinicaltrials.gov/search?intr=MCLA-129

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [MET](https://onco.cc/targets/met/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/), [Genmab](https://onco.cc/companies/genmab/)
- trials: [A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct07208149/), [Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina](https://onco.cc/trials/nct04868877/), [Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.](https://onco.cc/trials/nct07448116/), [Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.](https://onco.cc/trials/nct06885840/), [Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors](https://onco.cc/trials/nct04930432/)
- key papers: [MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma](https://onco.cc/key-papers/paper-monumental-1-talquetamab-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/mcla-129.json